Synthesis, crystal structure analysis, and pharmacological characterization of disila-bexarotene, a disila-analogue of the RXR-selective retinoid agonist bexarotene

Organometallics

Volumn 24, Issue 13, 2005, Pages 3192-3199

  Daiss, Jürgen O ^a   Burschka, Christian ^a   Mills, John S ^b   Montana, John G ^b   Showell, Graham A ^b   Fleming, Ian ^c   Gaudon, Claudine ^d   Ivanova, Diana ^d   Gronemeyer, Hinrich ^d   Tacke, Reinhold ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Paradigm Therapeutics Ltd   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYSIS; CRYSTAL STRUCTURE; KETONES; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; OLEFINS; SINGLE CRYSTALS; SUBSTITUTION REACTIONS; X RAY DIFFRACTION;

RXR-SELECTIVE RETINOID AGONIST BEXAROTENE; SATURATED RINGS; SINGLE-CRYSTAL X-RAY DIFFRACTION; TWOFOLD SILA-SUBSTITUTION;

SYNTHESIS (CHEMICAL);

EID: 23144441588     PISSN: 02767333     EISSN: None     Source Type: Journal    
DOI: 10.1021/om040143k     Document Type: Article

References (60)

1. Syntheses and biological studies: (a) Boehm, M. F.; Heyman, R. A.; Zhi, L. (Inventors), Ligand Pharmaceuticals Inc., San Diego, CA. PCT Int. Pat. Appl. WO 93/21146 A1 (Oct 28, 1993); Chem. Abstr. 1994, 120, 217004k.
2. (b) Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. J. Med. Chem. 1994, 37, 2930-2941.
3. (c) Boehm, M. F.; Zhang, L.; Zhi, L.; McClurg, M. R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, P. J. A.; Heyman, R. A.; Nadzan, A. M. J. Med. Chem. 1995, 38, 3146-3155.
4. (d) Nadzan, A. M.; Boehm, M. F.; Zhang, L.; Badea, B. A.; Zhi, L.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; McClurg, M. R.; Davies, P. J. A.; Heyman, R. A. Eur. J. Med. Chem. 1995, 30 (Suppl.; Proceedings of the 13th International Symposium on Medicinal Chemistry, 1994), 519s-533s.
5. (e) Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W.; Pfahl, M.; Lee, M.-O.; Shroot, B.; Pfahl, M. J. Med. Chem. 1995, 38, 3368-3383.
6. (f) Zhang, L.; Badea, B. A.; Enyeart, D.; Berger, E. M.; Mais, D. E.; Boehm, M. F. J. Labeled Comp. Radiopharm. 1995, 36, 701-712.
7. (g) Kizaki, M.; Dawson, M. L; Heyman, R.; Elstner, E.; Morosetti, R.; Pakkala, S.; Chen, D.-L.; Ueno, H.; Chao, W.; Morikawa, M.; Ikeda, Y.; Heber, D.; Pfahl, M.; Koeffler, H. P. Blood 1996, 87, 1977-1984.
8. (h) Farmer, L. J.; Zhi, L.; Jeong, S.; Kallel, E. A.; Croston, G.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Bioorg. Med. Chem. Lett. 1997, 7, 2747-2752.
9. (i) Shirley, M. A.; Wheelan, P.; Howell, S. R.; Murphy, R. C. Drug Metab. Disp. 1997, 25, 1144-1149.
10. (j) Sun, S.-Y.; Yue, P.; Dawson, M. I.; Shroot, B.; Michel, S.; Lamph, W. W.; Heyman, R. A.; Teng, M.; Chandraratna, R. A. S.; Shudo, K.; Hong, W. K.; Lotan, R. Cancer Res. 1997, 07, 4931-4939.
11. (k) Faul, M. M.; Ratz, A. M.; Sullivan, K. A.; Trankle, W. G.; Winneroski, L. L. J. Org. Chem. 2001, 66, 5772-5782.
12. (l) Howell, S. R.; Shirley, M. A.; Grese, T. A.; Neel, D. A.; Wells, K. E.; Ulm, E. H. Drug Metab. Disp. 2001, 29, 990-998.
13. (m) Zhang, C.; Hazarika, P.; Ni, X.; Weidner, D. A.; Duvic, M. Clin. Cancer Res. 2002, 8, 1234-1240.
14. Clinical trials for the treatment of cutaneous T-cell lymphoma: (a) Rizvi, N. A.; Marshall, J. L.; Dahut, W.; Ness, E.; Truglia, J. A.; Loewen, G.; Gill, G. M.; Ulm, E. H.; Geiser, R.; Jaunakais, D.; Hawkins, M. J. Clin. Cancer Res. 1999, 5, 1658-1664.
15. (b) Bedikian, A. Y.; Plager, C.; Papadopoulos, N.; Ellerhorst, J.; Smith, T.; Benjamin, R. S. Oncol. Rep. 2000, 7, 883-886.
16. (c) Heald, P. Clin. Lymphoma 2000, 1, S45-S49.
17. (d) Prince, H. M.; McCormack, C.; Ryan, G.; Baker, C.; Rotstein, H.; Davison, J.; Yocum, R. Australasian J. Dermatol. 2001, 42, 91-97.
18. (e) Duvic, M.; Martin, A. G.; Kim, Y.; Olsen, E.; Wood, G. S.; Crowley, C. A.; Yocum, R. C. Arch. Dermatol. 2001, 137, 581-593.
19. (f) Cheng, S. X.; Kupper, T. Arch. Dermatol. 2001, 137, 649-652.
20. (g) Duvic, M.; Hymes, K.; Heald, P.; Breneman, D.; Martin, A. G.; Myskowski, P.; Crowley, C.; Yocum, R. C. J. Clin. Oncol. 2001, 19, 2456-2471.
21. (h) Breneman, D.; Duvic, M.; Kuzel, T.; Yocum, R.; Truglia, J.; Stevens, V. J. Arch. Dermatol. 2002, 138, 325-332.
22. (i) Liu, H. L.; Kim, Y. H. Arch. Dermatol. 2002, 138, 398-399.
23. (j) Heald, P.; Mehlmauer, M.; Martin, A. G.; Crowley, C. A.; Yocum, R. C.; Reich, S. D. J. Am. Acad. Dermatol. 2003, 49, 801-815.
24. Clinical trials for the treatment of other types of cancer: (a) Miller, V. A.; Benedetti, F. M.; Rigas, J. R.; Verret, A. L.; Pfister, D. G.; Straus, D.; Kris, M. G.; Crisp, M.; Heyman, R.; Loewen, G. R.; Truglia, J. A.; Warrell, R. P., Jr. J. Clin. Oncol. 1997, 15, 790-795.
25. (b) Khuri, F. R.; Rigas, J. R.; Figlin, R. A.; Gralla, R. J.; Shin, D. M.; Munden, R.; Fox, N.; Huyghe, M. R.; Kean, Y.; Reich, S. D.; Hong, W. K. J. Clin. Oncol. 2001, 19, 2626-2637.
26. (c) Esteva, F. J.; Glaspy, J.; Baidas, S.; Laufinan, L.; Hutchins, L.; Dickler, M.; Tripathy, D.; Cohen, R.; DeMichele, A.; Yocum, R. C.; Osborne, C. K.; Hayes, D. F.; Hortobagyi, G. N.; Winer, E.; Demetri, G. D. J. Clin. Oncol. 2003, 21, 999-1006.
27. Reviews dealing with bexarotene and other retinoids: (a) Hurst, R. E. Curr. Opin. Invest. Drugs 2000, 1, 514-523.
28. (b) Lowe, M. N.; Plosker, G. L. Am. J. Clin. Dermatol. 2000, 1, 245-250.
29. (c) Miller, A. B.; Nettesheim, P.; Stewart, B. W. Asian Pacific J. Cancer Prey. 2000, 1, 195-202.
30. (d) Kagechika, H. IDrugs 2000, 3, 73-83.
31. (e) Altucci, L.; Gronemeyer, H. Nat. Rev. Cancer 2001, 7, 181-193.
32. (f) Zouboulis, C. C. Skin Pharmacol. Appl. Skin Physiol. 2001, 14, 303-315.
33. (g) Wong, S.-F. Ann. Pharmacother. 2001, 35, 1056-1065.
34. (h) Camacho, L. H. J. Biol. Regul. Homeost. Agents 2003, 17, 98-114.
35. Review: Bains, W.; Tacke, R. Curr. Opin. Drug Discovery Dev. 2003, 6, 526-543 and references therein.
36. Original publications: (a) Tacke, R.; Merget, M.; Bertermann, R.; Bernd, M.; Beckers, T.; Reissmann, T. Organometallics 2000, 19, 3486-3497.
37. (b) Merget, M.; Günther, K.; Bernd, M.; Günther, E.; Tacke, R. J. Organomet. Chem. 2001, 628, 183-194.
38. (c) Tacke, R.; Kornek, T.; Heinrich, T.; Burschka, C.; Penka, M.; Pülm, M.; Keim, C.; Mutschier, E.; Lambrecht, G. J. Organomet. Chem. 2001, 640, 140-165.
39. (d) Tacke, R.; Handmann, V. I.; Kreutzmann, K.; Keim, C.; Mutschler, E.; Lambrecht, G. Organometallics 2002, 21, 3727-3732.
40. (e) Tacke, R.; Heinrich, T. Silicon Chem. 2002, 1, 35-39.
41. (f) Tacke, R.; Handmann, V. I.; Bertermann, R.; Burschka, C.; Penka, M.; Seyfried, C. Organometallics 2003, 22, 916-924.
42. (g) Heinrich, T.; Burschka, C.; Warneck, J.; Tacke, R. Organometallics 2004, 23, 361-366.
43. (h) Tacke, R.; Heinrich, T.; Bertermann, R.; Burschka, C.; Harnacher, A. ; Kassack, M. U. Organometallics 2004, 23, 4468-4477.
44. (i) Tacke, R.; Schmid, T.; Penka, M.; Burschka, C.; Bains, W.; Warneck, J. Organometallics 2004, 23, 4915-4923.
45. (j) Daiss, J. O.; Penka, M.; Burschka, C.; Tacke, R. Organometallics 2004, 23, 4987-4994.
46. Review: Laudet, V.; Gronemeyer, H. The Nuclear Receptor FactsBook; Academic Press: San Diego, CA, 2002, and references therein.
47. (a) Bourguet, W.; Germain, P.; Gronemeyer, H. Trends Pharmacol. Sci. 2000, 21, 381-388.
48. (b) Germain, P.; Iyer, J.; Zechel, C.; Gronemeyer, H. Nature 2002, 415, 187-192.
49. (c) Gronemeyer, H.; Gustafsson, J. A.; Laudet, V. Nat. Rev. Drug Discovery 2004, 3, 950-964.
50. Montana, J. G.; Showell, G. A.; Fleming, I.; Tacke, R.; Daiss, J. (Inventors), Amedis Pharmaceuticals Ltd., Cambridge, U.K. PCT Int. Pat. Appl. WO 2004/048390 A1 (June 10, 2004).
51. Vollhardt, K. P. C. Angew. Chem. 1984, 96, 525-541;
52. Angew. Chem., Int. Ed. Engl. 1984, 23, 539-556.
53. The hydrogen-bonding system was analyzed by using the program system PLATON: Spek, A. L. PLATON; University of Utrecht, Utrecht, The Netherlands, 1998. In this context, see also: Jeffrey, G. A.; Saenger, W. Hydrogen Bonding in Biological Structures; Springer-Verlag: Berlin, Germany, 1991; pp 15-24.
54. Kusumoto, T.; Hiyama, T. Chem. Lett. 1988, 1149-1152.
55. (a) Sheldrick, G. M. SHELXS-97; University of Göttingen, Göttingen, Germany, 1997.
56. (b) Sheldrick, G. M. Acta Crystallogr., Sect. A 1990, 46, 467-473.
57. Sheldrick, G. M. SHELXL-97; University of Göttingen, Göttingen, Germany, 1997.
58. Chen, J.-Y.; Penco, S.; Ostrowski, J.; Balaguer, P.; Pons, M.; Starrett, J. E.; Reczek, P.; Chambon, P.; Gronemeyer, H. EMBO J. 1995, 14, 1187-1197.
59. te Riele, H.; Maandag, E. R.; Clarke, A.; Hooper, M.; Berns, A. Nature 1990, 348, 649-651.
60. Nagpal, S.; Friant, S.; Nakshatri, H.; Chambon, P. EMBO J. 1993, 12, 2349-2360.